Inhibition of cholesteryl ester transfer protein (CETP): Different in vitro characteristics of RO4607381/JTT-705 and torcetrapib (TOR)

被引：16
|
作者：
Niesor, E. J. [1 ]
von der Marck, E. [1 ]
Brousse, M. [1 ]
Maugeais, C. [1 ]
机构：
[1] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
ATHEROSCLEROSIS | 2008年 / 199卷 / 01期
关键词：
D O I：
10.1016/j.atherosclerosis.2008.04.024
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [1] THE CARDIOVASCULAR SAFETY OF THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR, RO4607381/JTT-705: PHASE II FINDINGS
    Stroes, E. S.
    Kastelein, J. J.
    Kallend, D.
    Steiner, G.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 12 - 12
  • [2] SAFETY PROFILE OF THE CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR RO4607381/JTT-705: RESULTS FROM PHASE II TRIALS
    Buckley, B.
    Kallend, D.
    Stein, E. A.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 208 - 208
  • [3] No Increase in the In Vitro Production of Aldosterone or the Expression of CYP11B2 with the CETP Modulator Dalcetrapib (RO4607381/JTT-705), in Contrast with Torcetrapib
    Capponi, Alessandro M.
    Clerc, Roger G.
    Campos, Luciana
    Perez, Anne
    Garriz, Jose M. Rincon
    Maugeais, Cyrille
    Niesor, Eric J.
    [J]. CIRCULATION, 2008, 118 (18) : S452 - S452
  • [4] Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381
    不详
    [J]. Drugs in R & D, 2010, 10 (1) : 33 - 36
  • [5] Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial
    Stein, Evan A.
    Roth, Eli M.
    Rhyne, James M.
    Burgess, Tracy
    Kallend, David
    Robinson, Jennifer G.
    [J]. EUROPEAN HEART JOURNAL, 2010, 31 (04) : 480 - 488
  • [6] Inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia
    Kulvenhoven, JA
    de Grooth, GJ
    Kawamura, H
    Klerkx, AH
    Wilhelm, F
    Kastelein, JJ
    [J]. CIRCULATION, 2004, 110 (17) : 144 - 144
  • [7] JTT-705 -: Treatment of lipoprotein disorders cholesteryl ester transfer protein inhibitor
    Alegret, M
    Silvestre, JS
    Castañer, J
    [J]. DRUGS OF THE FUTURE, 2004, 29 (08) : 787 - 792
  • [8] The efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705
    De Grooth, GJ
    Kastelein, JJP
    [J]. CIRCULATION, 2001, 104 (17) : 176 - 176
  • [9] COMPARISON OF EFFECTS OF TORCETRAPIB AND RO4607381/JTT-705 ON BLOOD PRESSURE AND TISSUE EXPRESSION OF RENIN-ANGIOTENSIN SYSTEM-RELATED GENES IN RATS
    Kastelein, J. J.
    Stroes, E. S.
    Benardeau, A.
    Blum, D.
    Clerc, R. G.
    Campos, L.
    Niesor, E. J.
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 42 - 42
  • [10] Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with Pravastatin in type II dyslipidemia
    Kuivenhoven, JA
    de Grooth, GJ
    Kawamura, H
    Klerkx, AH
    Wilhelm, F
    Trip, MD
    Kastelein, JJP
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (09): : 1085 - 1088
12345